Arrowhead Pharmaceuticals Inc

Quantli Newsdesk

· 24 days ago

Arrowhead Pharmaceuticals reported positive Phase 3 results for plozasiran in severe hypertriglyceridemia, with the drug meeting all primary and secondary endpoints. The company plans to submit a supplemental new drug application to expand plozasiran's approved use before year-end.